89bio Inc (ETNB)
9.22
+0.36
(+4.06%)
USD |
NASDAQ |
May 03, 16:00
9.21
-0.01
(-0.11%)
After-Hours: 20:00
89bio Research and Development Expense (Quarterly): 33.59M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 33.59M |
| September 30, 2023 | 31.42M |
| June 30, 2023 | 34.92M |
| March 31, 2023 | 22.31M |
| December 31, 2022 | 19.06M |
| September 30, 2022 | 22.20M |
| June 30, 2022 | 19.69M |
| March 31, 2022 | 19.85M |
| December 31, 2021 | 20.98M |
| September 30, 2021 | 23.59M |
| June 30, 2021 | 15.63M |
| Date | Value |
|---|---|
| March 31, 2021 | 10.13M |
| December 31, 2020 | 8.77M |
| September 30, 2020 | 11.21M |
| June 30, 2020 | 8.443M |
| March 31, 2020 | 7.778M |
| December 31, 2019 | 7.192M |
| September 30, 2019 | 6.68M |
| June 30, 2019 | 3.165M |
| March 31, 2019 | 4.309M |
| December 31, 2018 | 3.692M |
| September 30, 2018 | 3.289M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.165M
Minimum
Jun 2019
34.92M
Maximum
Jun 2023
17.19M
Average
19.06M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 70.64M |
| Akero Therapeutics Inc | 53.39M |
| Viking Therapeutics Inc | 24.10M |
| Galectin Therapeutics Inc | 8.228M |
| Terns Pharmaceuticals Inc | 17.46M |